Kitaoka H
Gan No Rinsho. 1984 May;30(6 Suppl):741-8.
Based on experimental study that the growth of diffuse carcinoma of the stomach depended on sex hormone, chemo-endocrine therapy using an anti-estrogen after gastrectomy for female patients are carrying out in National Cancer Center Hospital since 1980. The results are as follows. The cumulative 3 year survival rate in 21 patients with chemo-endocrine therapy (TAM+) revealed significant higher (45.8%) than those (7.4%) in 23 patients with chemotherapy alone (TAM-). The results of TAM(+) in curatively resected cases (8 cases) were both 100% of 2 and 3 year survival rate with 2 recurrent cases. In TAM(-) 10 cases, 2 and 3 year survival rate showed 56.0% and 20.0% respectively (P less than 0.01). This study suggests that the chemo-endocrine therapy may be a new adjuvant therapy in female patients with diffuse carcinoma of the stomach.
基于弥漫性胃癌的生长依赖于性激素的实验研究，自1980年起，日本国立癌症中心医院对女性胃癌患者在胃切除术后采用抗雌激素进行化学内分泌治疗。结果如下。21例接受化学内分泌治疗（TAM+）患者的3年累积生存率显著高于23例单纯化疗（TAM-）患者（分别为45.8%和7.4%）。在根治性切除病例（8例）中，TAM（+）组2年和3年生存率均为100%，有2例复发。在TAM（-）组10例中，2年和3年生存率分别为56.0%和20.0%（P<0.01）。本研究表明，化学内分泌治疗可能是女性弥漫性胃癌患者一种新的辅助治疗方法。
